Physician profile
John Clark
NPI 1578631784
$8,272.14
in general payments reported to CMS, 2019-2025
38 companies · $1,370 in 2025
The $1,370 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $854 · 2020: $1,372 · 2021: $533 · 2022: $2,565 · 2023: $636 · 2024: $942 · 2025: $1,370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,947.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,632.21 | 2021-2023 | Ellipsys Vascular Access System |
| Bard Peripheral Vascular, INC. | $1,318.25 | 2019-2022 | |
| Vifor Pharma, INC. | $532.01 | 2019-2025 | Veltassa |
| Novartis Pharmaceuticals Corporation | $488.36 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $475.33 | 2021-2024 | |
| Opko Pharmaceuticals, LLC | $406.70 | 2019-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $398.49 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals Lp | $397.08 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $339.41 | 2020-2025 | Tavneos, Parsabiv, Aranesp |
| Travere Therapeutics, INC. | $273.17 | 2021-2025 | |
| Avenu Medical INC. | $255.85 | 2019-2020 | |
| Calliditas Therapeutics US INC. | $210.69 | 2022-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.65 | 2024-2025 | Jardiance |
| Akebia Therapeutics INC | $181.96 | 2020-2024 | Auryxia, Vafseo |
| Takeda Pharmaceuticals U.S.A., INC. | $141.91 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $134.99 | 2022-2024 | Jesduvroq, Benlysta |
| Ardelyx, INC. | $110.67 | 2023-2025 | Ibsrela |
| Novo Nordisk INC | $98.26 | 2024-2025 | Ozempic, Rybelsus |
| Aurinia Pharma U.S., INC. | $91.48 | 2021-2023 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $84.78 | 2019-2022 | |
| Fresenius USA Marketing, INC. | $80.60 | 2019-2023 | Velphoro |
| Lilly USA, LLC | $74.52 | 2023-2024 | Jardiance |
| Horizon Therapeutics Plc | $63.83 | 2019-2023 | Krystexxa |
| Cycle Pharmaceuticals INC | $41.73 | 2025 | Venxxiva |
| Cormedix INC. | $38.51 | 2024 | Defencath |
| Apellis Pharmaceuticals, INC. | $38.03 | 2025 | Empaveli |
| Ani Pharmaceuticals, INC. | $31.52 | 2024 | Purified Cortrophin Gel |
| Ultragenyx Pharmaceutical INC. | $23.32 | 2021 | |
| Alnylam Pharmaceuticals INC. | $21.87 | 2022 | |
| Mallinckrodt Enterprises LLC | $17.12 | 2019 | |
| Acera Surgical, INC. | $16.81 | 2024 | Restrata Wound Matrix |
| Shire North American Group INC | $16.71 | 2019 | |
| Daiichi Sankyo INC. | $16.47 | 2022 | |
| Genentech USA, INC. | $15.73 | 2019 | |
| Baxter Healthcare | $14.12 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.